ADAM trial:

A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in Merkel cell carcinoma patients with clinically detected lymph node metastases NCT03271372; Shailender Bhatia et al.
A poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting presented data on the ADAM trial. This is the first-ever phase 3 trial in MCC and is a major academic collaboration across several US cancer centres. To view the poster, please click here (Attachment no. 5).